CAR-T cells target circulating TNF: from chronic injections to single infusion

A fundamentally different approach to autoimmune inflammation has demonstrated durable remission of rheumatoid arthritis in animal models using a single cell infusion. The core limitation of conventional anti-TNF therapies—drugs like adalimumab (Humira) requiring bimonthly injections—lies in their short half-lives and collateral suppression of broader immune competence. Researchers engineered T cells with CAR receptors based on TNFR1 ectodomain, capable of specifically recognizing and degrading circulating TNF without relying on the body's endogenous protein degradation machinery. To overcome the critical barrier of poor CAR-T expansion in immunocompetent hosts, they applied CRISPR-mediated double knockout of Bcor/Zc3h12a, generating long-lived T cells that persist without preconditioning. The paradigm shift emerging here is substantial: moving from chronic repeated drug administration to durable disease control via single intervention represents a conceptual leap relevant to anyone managing long-term autoimmune conditions.